Welcome to our dedicated page for Belite Bio news (Ticker: BLTE), a resource for investors and traders seeking the latest updates and insights on Belite Bio stock.
Belite Bio, Inc. reports clinical and regulatory developments for tinlarebant, an oral investigational therapy for degenerative retinal diseases. The company focuses on Stargardt disease type 1 (STGD1) and geographic atrophy in advanced dry age-related macular degeneration, with a program designed to reduce accumulation of bisretinoid toxins in the eye.
Recurring updates include DRAGON and DRAGON II Stargardt disease studies, PHOENIX geographic atrophy development, FDA interactions, scientific meeting presentations, investor-conference appearances, financial results, annual Form 20-F availability, and capital actions involving American Depositary Shares. Company news also covers corporate updates for a foreign private issuer whose securities trade under BLTE.
Belite Bio (BLTE) has submitted a New Drug Application in Japan for tinlarebant to treat Stargardt disease type 1 under the Sakigake Designation System.
The filing to Japan’s Ministry of Health, Labour, and Welfare runs in parallel with a U.S. NDA that the FDA has accepted with Priority Review and a Prescription Drug User Fee Act target action date of February 12, 2027. Tinlarebant is an investigational, once-daily oral therapy for this rare inherited retinal disease, which affects an estimated 9,500 people in Japan and currently has no approved treatments. If approved, tinlarebant could become both the first treatment for STGD1 and the first Sakigake-designated ophthalmology product in Japan.
Belite Bio (NASDAQ: BLTE), a clinical-stage drug developer focused on degenerative retinal diseases, will participate in four investor conferences in September 2026. These include Wells Fargo (Sept 8, Boston), Cantor (Sept 11, New York), Morgan Stanley (Sept 14, New York), and H.C. Wainwright (Sept 15, New York). Webcasts and 90-day replays will be available in the investor relations “Events” section on Belite Bio’s website.
Belite Bio (NASDAQ: BLTE) will host a Virtual Commercial Day on Wednesday, September 2, 2026, from 8:00–9:30 a.m. ET. The event will feature Belite Bio’s management, ophthalmology experts, and people living with Stargardt disease type 1 (STGD1), covering disease overview, unmet needs, and treatment landscape.
Management will discuss prelaunch preparedness and the potential commercial opportunity for tinlarebant in STGD1, if approved by the U.S. FDA. Tinlarebant’s NDA has Priority Review, with a PDUFA date of February 12, 2027. The webcast and replay will be available via Belite Bio’s investor relations site.
Belite Bio (NASDAQ: BLTE) announced that data from its Phase 3 DRAGON study of tinlarebant for Stargardt disease will be featured in multiple oral presentations at two major ophthalmology meetings in August 2026: the Schweizerische Ophthalmologische Gesellschaft (SOG) Annual Congress in Lausanne and the 19th Asia-Pacific Vitreo-retina Society (APVRS) Congress in Gold Coast.
At SOG, results from the Phase 3 DRAGON study in adolescent and adult Stargardt disease will be presented on August 27, 2026, 8:30–8:40 p.m. CEST at the SwissTech Convention Center. At APVRS, several sessions from August 28–30, 2026 will cover new insights, topline Phase 3 results, and an update on ABCA4-retinopathy therapy trials in Japan, all at the Gold Coast Convention & Exhibition Centre.
Belite Bio (NASDAQ: BLTE) reported unaudited Q2 2026 results and a corporate update highlighted by FDA acceptance of its NDA for tinlarebant for Stargardt disease type 1 with Priority Review and a PDUFA target action date of February 12, 2027. The completed Phase 3 DRAGON trial showed additional positive secondary endpoint data, with month‑25 qAF levels stable to slightly decreased (~2%) in tinlarebant‑treated subjects versus an approximate 20% increase in placebo.
Belite completed enrollment in the Phase 2/3 DRAGON II STGD1 trial (73 subjects) and the Phase 3 PHOENIX GA trial (530 subjects). As of June 30, 2026, cash and cash equivalents were $279.9 million and investments were $500.1 million. Q2 2026 R&D expenses were $18.2 million, SG&A expenses were $16.7 million, and net loss was $28.4 million, with non‑GAAP net loss of $21.6 million.
Belite Bio (NASDAQ: BLTE) announced that the U.S. FDA has accepted and granted Priority Review to its New Drug Application for tinlarebant to treat Stargardt Disease Type 1 (STGD1). The FDA set a PDUFA target action date of February 12, 2027.
The NDA is supported by the Phase 3 DRAGON trial, in which tinlarebant achieved a 35.7% reduction in the growth rate of atrophic retinal lesions versus placebo, measured as definitely decreased autofluorescence. Tinlarebant has been generally well tolerated, and, if approved, would be the first FDA-approved treatment for STGD1, which affects an estimated 53,000 people in the U.S.
Belite Bio (NASDAQ: BLTE) will host a webcast on Thursday, August 13, 2026, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss second quarter 2026 financial results and provide a business update. Investors can access the event via the provided webcast link or the company’s Investor Relations “Presentations & Events” webpage. A replay will be available for about 90 days.
Belite Bio (NASDAQ: BLTE) reported additional positive secondary endpoint data from its Phase 3 DRAGON trial of tinlarebant in Stargardt disease type 1, presented at the ASRS 2026 Annual Meeting. Tinlarebant is described as the first therapeutic candidate to demonstrate clinical efficacy in this indication, having met the primary endpoint.
According to Belite Bio, quantitative autofluorescence, a marker of toxic bisretinoid accumulation, remained stable to slightly decreased (around 2%) at month 25 in tinlarebant-treated subjects, versus an approximately 20% increase with placebo. The 104‑patient, 2:1 randomized trial previously showed a statistically significant 35.7% reduction in retinal lesion growth versus placebo, with tinlarebant reported as well tolerated. The company also completed a New Drug Application for tinlarebant to the U.S. FDA.
Belite Bio (NASDAQ: BLTE) will participate in a panel discussion at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference on Wednesday, July 22, 2026, at 3:00 pm ET. A live webcast and 90-day replay will be available via the company’s investor relations website.
Belite Bio (NASDAQ: BLTE), a clinical-stage drug development company focused on degenerative retinal diseases, will participate in a fireside chat at the Piper Sandler Virtual Ophthalmology Investor Symposium on July 9, 2026 at 12:30 pm ET.
The live webcast and 90-day replay will be available under “Events” in the investor relations section of the Belite Bio website.